Skip to main content
Vetoquinol SA logo

Vetoquinol SA — Investor Relations & Filings

Ticker · VETO ISIN · FR0004186856 LEI · 969500YP0AETQIK48R39 PA Manufacturing
Open in API
Filings indexed 299 across all filing types
Latest filing 2015-10-22 Earnings Release
Country FR France
Listing PA VETO

About Vetoquinol SA

https://www.vetoquinol.com/en

Vetoquinol SA is a global animal health company that researches, develops, produces, and markets veterinary medicines and non-medicinal products. The company provides solutions for both companion animals (cats and dogs) and livestock (cattle and pigs). Its product portfolio addresses a wide range of therapeutic areas, including mobility, dermatology, anti-parasitics, antibiotics, internal medicine, and behavior management. Founded in 1933, the independent, family-owned business focuses on innovation and maintaining a close relationship with veterinary professionals to support animal well-being.

Recent filings

Filing Released Lang Actions
Information financière du troisième trimestre
Earnings Release Classification · 95% confidence The document is a press release detailing Vetoquinol's sales performance for the first nine months of 2015. It provides key financial highlights, including revenue growth percentages, regional performance, and a breakdown of sales by product category. It does not constitute a full interim report (which would be a comprehensive financial document) but rather an initial announcement of quarterly/periodical financial results, which fits the definition of an Earnings Release (ER). 9M 2015
2015-10-22 French
Quarterly financial report / Third quarter financial report
Earnings Release Classification · 100% confidence The document is a press release detailing the company's revenue (Chiffre d'affaires) for the first nine months of 2015. It provides specific financial data, including growth percentages, regional performance, and a table comparing 2015 and 2014 figures. Since it is an initial announcement of quarterly/periodical financial results containing key highlights rather than a full comprehensive interim report, it is classified as an Earnings Release (ER). 9M 2015
2015-10-22 English
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Earnings Release Classification · 99% confidence The document is a press release announcing the European launch of a new veterinary drug, UPCARD©, for congestive heart failure in dogs. It details the product's innovation (torasemide-based diuretic), market impact, and includes a quote from the CEO. It also provides contact information for Investor Relations and announces the date for the next sales update (Q3 2015 sales). This type of announcement, focusing on a specific business development (product launch) and intended for investors/media, is typically classified as a general Regulatory Filing (RNS) or sometimes an Earnings Release (ER) if it were summarizing financial results. Since it is a specific business event announcement rather than a formal financial report (10-K, IR, ER), and it doesn't fit the other specific categories (like M&A, Capital Change, Dividend), the most appropriate general category is Regulatory Filings (RNS). It is too detailed for a simple Report Publication Announcement (RPA) as it contains substantive news, not just a notice of publication. Q3 2015
2015-09-14 English
Communiqués de mise à disposition de documents / Modalités de mise à disposition du rapport financier semestriel
Report Publication Announcement Classification · 100% confidence The document is a short press release (1973 characters) titled 'COMMUNIQUÉ DE MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL'. It does not contain the financial report itself, but rather announces that the report has been made available to the public and provides instructions on how to access it. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2015-07-30 French
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 98% confidence The document is titled 'Press Release' and provides key financial figures for 'H1 2015' (First Half 2015), including sales, EBITDA, and net income, comparing them to H1 2014. It explicitly states that the Board of Directors reviewed revenues and approved the H1 2015 financial statements. This content structure—a summary of period results released via press release—is characteristic of an Earnings Release (ER). It is not the comprehensive 'Interim Report' (IR) itself, but the initial announcement of the results. The document also mentions the 'Next update: Q3 2015 Sales – October 22, 2015', confirming its nature as a periodic results announcement. H1 2015
2015-07-30 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 95% confidence The document is a press release detailing the financial results for the first half (H1) of 2015 for Vétoquinol SA. It includes key financial metrics such as revenue, operating income, net income, and EBITDA, along with comparative data for the previous year. While it provides substantive financial data, it is structured as an earnings release (initial announcement of results) rather than a full interim report. It fits the definition of an Earnings Release (ER) as it highlights key financial performance indicators for a specific period. H1 2015
2015-07-30 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.